NewcelX CEO Issues Letter to Shareholders
NewcelX Ltd. - Ordinary Shares (NCEL)
Company Research
Source: PR Newswire
ZURICH, Nov. 4, 2025 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL), a Swiss clinical-stage biopharmaceutical company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, integrating regenerative medicine and neuroscience expertise within a unified platform, today issued a letter to its shareholders. Dear Shareholders, The future of NewcelX Ltd. (Nasdaq: NCEL) ("NewcelX" or the "Company") begins now. Our Company stands at a pivotal moment, where years of scientific innovation are converging with what we view as real opportunity. We believe that the next 12 months are positioned to redefine what we can achieve for patients and create meaningful value for our shareholders. Today, NewcelX is built on powerful innovative cell therapies and neuroscience programs, which we believe can be mo
Show less
Read more
Impact Snapshot
Event Time:
NCEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NCEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NCEL alerts
High impacting NewcelX Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
NCEL
News
- NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological InstitutePR Newswire
- NLS Pharmaceutics (NASDAQ:NCEL) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=NCEL&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreeMarketBeat
- NewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory BoardPR Newswire
- NewcelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd.PR Newswire